Once-Weekly Byetta LAR (exenatide long-acting release): So Far, It Works

| Jul 13, 2007

It's a fact that Byetta reduces A1c's, post-meal and fasting glucose levels, and weight in people with type 2 diabetes. The drawback is that it's another injection twice a day. In response, Amylin, the maker of Byetta, has developed exenatide LAR, a form of Byetta that is injected only once a week.

A phase 2 clinical trial recently published in Diabetes Care has found that like Byetta, exenatide LAR improves blood glucose control and causes weight loss in people with type 2 diabetes. In the placebo-controlled study, exenatide LAR was given subcutaneously once weekly for 15 weeks to 45 patients with type 2 diabetes. At the outset, they were not well controlled on metformin or with diet and exercise, and their average A1c was 8.5 percent. Each patient on exenatide LAR received either 0.8 or 2.0 mg.

Both doses of the LAR formula reduced fasting plasma glucose and average daily blood glucose, both of which increased in the placebo group. A1c's increased slightly in the placebo group but decreased in the exenatide LAR patients, by 1.4 points in the 0.8 mg group and by 1.7 points in the 2.0 mg. group. The 2.0 mg LAR group lost an average of 8.4 pounds, but the 0.8 mg group and the placebo group lost no weight. No one had to discontinue the treatment due to adverse events.

Source: Diabetes Care 2007

Click Here To View Or Post Comments

Categories: A1c Test, Blood Glucose, Byetta, Diabetes, Diabetes, Type 2 Issues, Type 2 Medications

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.